Disposable Components in Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Disposable Components in Aseptic Processing
The authors discuss current and future disposable technologies and outline the validation and qualification steps that would be required for a possible disposable process stream.


Pharmaceutical Technology


Conclusion

Many disposable devices are already available, most commonly as a single entity, but in some instances already connected (e.g, filter–bag or bioreactor–filter systems). Rapidly developing connectivity will enhance the development of connected, integral systems and potentially total disposable processes, at least in small volume scales. Some developments (e.g., filling lines) are still necessary. The last step in aseptic processing has not reached the level one finds in the intermediate steps.

The benefits of disposability within aseptic processes are obvious. Cleaning deficiencies are a common regulatory observation, which would be eliminated by disposable equipment use. The risk of cross contamination is greatly reduced. Moreover, disposable, aseptic connectivity will reduce the level of end-user manipulation within the process and therefore create higher safety. Disposability is also valuable from economic and environmental standpoints because there is a cost savings in cleaning solutions and copious amounts of water, as well as the high energy levels required to heat the cleaning solutions or steam sterilize reusable equipment.

Maik W. Jornitz* is group vice-president of marketing FT/FRT at Sartorius Stedim,
. Jean-Marc Cappia is group vice-president of marketing FMT at Sartorius Stedim SA. Theodore H. Meltzer is principle of Capitola Consultancy.

*To whom all correspondence should be addressed.

Additional reading

  • M.W. Jornitz et al., "Testing for the Optimal Filter Membrane," Genetic Engineering News 24 (13) (July 2004).
  • J. Mora et al., "Disposable Membrane Chromatography: Performance Analysis and Economic Cost Model," BioProcess Int. 4, 38–43 (2006).
  • PDA Technical Report 26: Liquid Sterilizing Filtration (Parenteral Drug Association, Bethesda, MD, 2008).
  • M. Prashad and K. Tarrach "Depth Filtration Aspects for the Clarification of CHO Cell-Derived Biopharmaceutical Feed Streams," FISE 9, 28–30 (2006).
  • P.M. Priebe, "Advances in Fluid Processing Technologies," presented at the PDA SciTech Conference, Orlando, March 2004.
  • M. Rios, "Disposable Filtration Lightens Cleaning and Validation Load," Pharm. Technol. 25 (9), (2003).
  • A. Sinclair and M. Monge, "Quantitative Economic Evaluation of Single Use Disposables in Bioprocessing," Pharma. Eng. 22 (3), 16–20 (May–June 2002).
  • J.X. Zhou and T. Tressel, "Membrane Chromatography as a Robust Purification System for Large-Scale Antibody Production," BioProcess Int. 3, 32–37 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here